September 18, 2015

Bayer aligns organization with Life Science businesses

Leverkusen, Germany, September 18, 2015 -


- Operational management in three divisions: Pharmaceuticals, Consumer Health
and Crop Science

- Dieter Weinand, Erica Mann and Liam Condon appointed to the Bayer Board of
Management

- Dr. Hartmut Klusik succeeds Michael König as a member of the Board of
Management and Labor Director

- Greater integration and stronger focus on the Bayer corporate brand

- Implementation to start on January 1, 2016


Following the economic and legal separation of Covestro, Bayer is charting the
course for its successful development as a Life Science company. On Friday, the
Supervisory Board approved the reorganization proposed by the Board of
Management. From January 1, 2016, the company's business will be managed by
three divisions: Pharmaceuticals, Consumer Health and Crop Science. The present
structure of a strategic management holding company and operational subgroups
will be replaced by an integrated organization under the umbrella of the strong
Bayer brand. "The aim of the new organization is to provide the best-possible
support to Bayer's strategy as a leading Life Science company and to put
ourselves in an even stronger position vis-à-vis our competitors. We can
achieve this by further improving our innovation strength, sharpening our
customer focus and strengthening business process excellence," said Dr. Marijn
Dekkers, Chairman of the Board of Management of Bayer AG.

In the new organization, the Board of Management of Bayer AG will also hold
overall responsibility for business operations. For this reason, the
Supervisory Board resolved to appoint the heads of the divisions - Dieter
Weinand (Pharmaceuticals), Erica Mann (Consumer Health) and Liam Condon (Crop
Science) - to the Board of Management effective January 1, 2016. On the same
date, Dr. Hartmut Klusik will also join the Board of Management of Bayer AG as
the new Labor Director and Board member responsible for Human Resources,
Technology and Sustainability. He will succeed Michael König, who has requested
that his contract not be extended.

"In recent years, Bayer has continued developing its portfolio with a
significant focus on the Life Sciences. The company's very strong position at
this time enables it to concentrate exclusively on these businesses. The
logical conclusion of this is greater integration of the organization," said
Werner Wenning, Chairman of the Supervisory Board of Bayer AG. Concerning the
changes on the Board of Management, Wenning added: "We are convinced that the
greater integration of strategic and operational roles will take Bayer forward
and we have expanded the roles of the Board of Management members accordingly.
We wish the Board of Management in its new constellation every success. It is
with regret that we say farewell to Michael König. We would like to thank him
most sincerely for his valuable contribution and wish him all the best for the
future."

As part of the reorganization, the Bayer HealthCare subgroup will be dissolved.
The Radiology business will be assigned to the Pharmaceuticals Division.
Consumer Health will comprise the present Consumer Care Division. The Bayer
CropScience subgroup will become the Crop Science Division. As a business unit,
Animal Health will report directly to Liam Condon.

The divisions are to focus on core competencies close to their businesses -
research and development, production, and sales & marketing. They will be
supported by integrated functions such as Human Resources and Procurement, and
by global services. Within this context, Bayer's existing Technology Services
company will become the Engineering & Technology function. Bayer Business
Services, the company in which information technology and business support
services are bundled, will remain a separate legal entity that is to see
further expansion.

This greater integration will also be reflected in Bayer's brand architecture.
In the future, the company will focus exclusively on the Bayer corporate brand
and its product brands. The divisions will not have separate brand identities.

Job numbers to remain stable in the years ahead

Despite the organizational changes, job numbers are expected to remain stable
in the years ahead, both worldwide and in Germany. In a joint declaration
issued by management and the employee representatives, key principles relating
to the organizational changes have been defined. "We expressly welcome the fact
that the subgroups and Bayer Technology Services are being reintegrated under
the roof of Bayer AG. Our joint declaration guarantees continued security,
trust and motivation for the employees," said Oliver Zühlke, Chairman of the
Central Works Council of Bayer AG. "We have also been able to bring about a
return to the collective agreement of the German Mining, Chemical and Energy
Industrial Union (IG BCE) for our colleagues at Bayer Business Services."

Bayer as a pure Life Science company with outstanding perspectives

"Our mission of 'Science For A Better Life' ideally fits Bayer as a Life
Science company. Ultimately, all activities of Bayer have one and the same
goal: improving people's lives all over the world," said Dekkers. The
challenges are immense. The aim is to provide better medical care and ensure an
adequate supply of high-quality food for the growing global population. This
can only be achieved with Life Science innovations. "We have leading positions
in attractive and growing markets and our business is diversified and balanced
in terms of economic cycles and risks," Dekkers continued. Moreover, in light
of the many commonalities between the biochemical processes in living
organisms, the portfolio also offers interesting opportunities, especially in
research.

The future product portfolio of the Pharmaceuticals Division brings together
prescription medicines from the general medicine and specialty pharmaceuticals
categories and also the Radiology business. The Consumer Health Division will
encompass globally known consumer brands from the allergy, analgesic,
cardiovascular risk prevention, cough, cold and flu, dermatology, foot care,
gastrointestinal, dietary supplement and sun protection categories. The Crop
Science Division - Bayer's agriculture business - is active in the seed,
chemical and biological crop protection and non-agricultural pest control
markets. Animal Health provides products and solutions to prevent and treat
diseases in companion and farm animals.

Bayer Board of Management to be enlarged and assume overall operational
responsibility

Effective January 1, 2016, the Board of Management of Bayer AG will comprise
eight members headed by Chairman Dr. Marijn Dekkers. Johannes Dietsch will be
responsible for Finance; Werner Baumann will oversee Strategy and Portfolio
Management; and Kemal Malik will have responsibility for Innovation. Michael
König will be leaving the company at his own request on expiration of his
contract. Dr. Hartmut Klusik, currently responsible for Product Supply on the
Board of Management of Bayer HealthCare AG, will be the new Labor Director and
Board member responsible for Human Resources, Technology and Sustainability. As
part of the reorganization, the Board of Management areas for Innovation and
Technology will be additionally strengthened. The Board of Management will also
be enlarged to include the three divisional heads: Dieter Weinand
(headquartered in Berlin, Germany), Erica Mann (headquartered in the future in
Basel, Switzerland) and Liam Condon (headquartered in Monheim, Germany).

Dieter Weinand (55) was appointed to the Bayer HealthCare Executive Committee
as head of the Pharmaceuticals Division on August 1, 2014. Before moving to
Bayer HealthCare, he was President, Global Commercialization & Portfolio
Management at Otsuka Pharmaceutical Development & Commercialization, Inc. in
Princeton, New Jersey, United States. Prior to that, he held various
responsibilities in commercial, operational and strategic roles at a number of
pharmaceutical companies including Pfizer and Bristol-Myers Squibb. He was born
in Boppard, Germany, and earned a B.A. in biology from Concordia College, New
York, and an M.S. in pharmacology and toxicology from Long Island University,
New York. Weinand is married and has three children.

Erica Mann (56) was appointed to the Bayer HealthCare Executive Committee as
head of the Consumer Care Division in mid-March 2011. She also chairs the World
Self Medication Industry Association. Before joining Bayer, her roles included
Managing Director of Wyeth in Australia and New Zealand from 2003. In April
2009, she became Senior Vice President for the global Nutrition business.
Following the acquisition of Wyeth by Pfizer, Mann moved to the United States,
where she was President and General Manager of Pfizer's Nutrition Division and
a member of that company's Senior Management Team. Mann was born in
Vereeniging, South Africa. She holds a degree in analytical chemistry and a
marketing management diploma from the Institute of Marketing Management in
Johannesburg, South Africa. Erica Mann has two adult children.

Liam Condon (47) has been Chairman of the Executive Committee of Bayer
CropScience and Chairman of the Board of Management of Bayer CropScience AG
since December 1, 2012. Prior to that, he held various positions of increasing
responsibility for Bayer's Pharmaceuticals Division in Europe and Asia. In
January 2010, Condon was appointed Managing Director of Bayer HealthCare
Germany and head of Bayer's Pharmaceuticals business in Germany. Condon is a
member of the Board of Directors of CropLife International. He studied
international business at Dublin City University, Ireland, and, with a
scholarship from the German Academic Exchange Service (DAAD), at the Technical
University of Berlin, Germany. Condon is married and has two sons.

Dr. Hartmut Klusik (59) was appointed to the Bayer HealthCare Executive
Committee on July 5, 2005, and is responsible for Product Supply at Bayer
HealthCare. He is also a member of the management boards of Bayer HealthCare AG
and Bayer Pharma AG. Klusik began his career at Bayer's former Wolff Walsrode
AG subsidiary in 1984, where he held various positions of increasing
responsibility. In 1990, he transferred to Bayer AG and was appointed head of
crop protection production in Brazil. This was followed by assignments in the
United States and Australia. In 1997, Klusik took charge of crop protection
active ingredient production in Dormagen and, in 2002, became head of active
ingredient production for Bayer CropScience in Monheim. In early 2005, he was
appointed head of the Technical Operations Committee at Bayer HealthCare.
Hartmut Klusik was born in Niederwald, Germany. He graduated with a doctorate
in chemistry from the Philipps University in Marburg. Klusik is married and has
two children.

Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in Bayer's public reports, which are available on the
Bayer website at www.bayer.com. The company assumes no liability whatsoever to
update these forward-looking statements or to conform them to future events or
developments.